Oncology · NSCLCTrial Updateclinicalmid-term

Janssen's Amivantamab and Docetaxel Combo in NSCLC Enters Phase 1/2 Trials

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Janssen35 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 6:04:01 AM

Assessment confidence: 84% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing Phase 1/2 trial of Janssen's amivantamab and docetaxel combination therapy is significant as it targets a niche patient population in metastatic NSCLC. Positive trial outcomes could enhance Janssen's competitive positioning and influence treatment paradigms in this therapeutic area. Regulatory context from MHRA (MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer) supports the near-term read. Assessment grounded in 6 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should monitor the trial outcomes closely, as positive results could enhance Janssen's standing in the competitive landscape of NSCLC treatments. The strongest clinical anchor is A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer (ClinicalTrials.gov), sub-indication match (lung cancer); entity match (janssen). In lung cancer, 0 regulatory and 3 competitive items passed relevance filtering for Janssen.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC (Humanexa Signals) — sub-indication match (lung cancer); sponsor/company relevance (pfizer). Secondary pressure from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial.

Regulatory Outlook

Regulatory risk is concentrated around The trial's outcomes will be critical for determining the path to regulatory approval, particularly if the combination demonstrates significant efficacy in a previously underserved patient population..

Key Risks

Elevated medium regulatory exposure for Janssen could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.

Key Opportunities

If successful, this combination therapy could capture market share from existing treatments, potentially leading to increased revenue for Janssen in the NSCLC segment.
Lead sponsor: Janssen Research & Development, LLC.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
Oncology · KRAS G12C NSCLC · Trial Update · Divarasib's positive results position it as a potential new standard of care, challenging the current market leaders sotorasib and adagrasib.
Portfolio teams should monitor the trial outcomes closely, as positive results could enhance Janssen's standing in the competitive landscape of NSCLC treatments.

What Would Change This Assessment

This becomes more urgent if Key milestones include the determination of the recommended Phase 2 dose and subsequent efficacy results from the expansion phase.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Entity match (janssen)
FDA document
View source
Study of Amivantamab, Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Entity match (janssen)
FDA document
View source
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
ClinicalTrials.govmedium relevance
Sub-indication match (lung cancer)
FDA document
View source
Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Pfizer)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Roche)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Roche)
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Mercklow relevance
Sponsor/company relevance (Merck)
FDA document
View source

Safety and immunogenicity of COVID-19-Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Janssen
Amivantamab
Docetaxel

Commercial impact

medium

If successful, this combination therapy could capture market share from existing treatments, potentially leading to increased revenue for Janssen in the NSCLC segment.

Regulatory impact

medium

The trial's outcomes will be critical for determining the path to regulatory approval, particularly if the combination demonstrates significant efficacy in a previously underserved patient population.

What to watch

Key milestones include the determination of the recommended Phase 2 dose and subsequent efficacy results from the expansion phase.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.